6C4D

ICD-11 MMS 2026-01

Disorders due to use of dissociative drugs including ketamine or phencyclidine (PCP)

Description

Disorders due to use of dissociative drugs including ketamine and phencyclidine (PCP) are characterised by the pattern and consequences of dissociative drug use. Dissociative drugs include ketamine and PCP and their (comparatively rare) chemical analogues. Ketamine is an intravenous anaesthetic widely used in low- and middle-income countries, particularly in Africa, and in emergency situations. Ketamine is also undergoing evaluation for treatment of some mental disorders (e.g., treatment resistant Depressive Disorders). It is also a widespread drug of nonmedical use in many countries and may be taken by the oral or nasal routes or injected. It produces a sense of euphoria but depending on the dose, emergent hallucinations and dissociation are recognised as unpleasant side effects. Phencyclidine has a more restricted worldwide distribution and also has euphoric and dissociative effects. Its use may result in bizarre behaviour uncharacteristic for the individual, including self-harm. Dissociative Drug Dependence is described but a withdrawal syndrome is not recognized by most authorities. Several Dissociative Drug-Induced Mental Disorders are recognised.

Excludes

  • QE11.7 – Hazardous use of dissociative drugs including ketamine or PCP

Exclusions from above levels

  • QE62 – Uncomplicated bereavement
  • QE84 – Acute stress reaction

Child codes

  • 6C4D.0 – Episode of harmful use of dissociative drugs including ketamine or PCP
  • 6C4D.1 – Harmful pattern of use of dissociative drugs, including ketamine or PCP
  • 6C4D.2 – Dissociative drug dependence including ketamine or PCP
  • 6C4D.3 – Dissociative drug intoxication including Ketamine or PCP
  • 6C4D.4 – Dissociative drug-induced delirium including ketamine or PCP
  • 6C4D.5 – Dissociative drug-induced psychotic disorder including ketamine or PCP
  • 6C4D.6 – Certain specified dissociative drug-induced mental or behavioural disorders, including ketamine or phencyclidine (PCP)
  • 6C4D.Y – Other specified disorders due to use of dissociative drugs including ketamine or phencyclidine (PCP)
  • 6C4D.Z – Disorders due to use of dissociative drugs including ketamine or phencyclidine (PCP), unspecified

Sibling codes

  • 6C40 – Disorders due to use of alcohol
  • 6C41 – Disorders due to use of cannabis
  • 6C42 – Disorders due to use of synthetic cannabinoids
  • 6C43 – Disorders due to use of opioids
  • 6C44 – Disorders due to use of sedatives, hypnotics or anxiolytics
  • 6C45 – Disorders due to use of cocaine
  • 6C46 – Disorders due to use of stimulants including amphetamines, methamphetamine or methcathinone
  • 6C47 – Disorders due to use of synthetic cathinones
  • 6C48 – Disorders due to use of caffeine
  • 6C49 – Disorders due to use of hallucinogens
  • 6C4A – Disorders due to use of nicotine
  • 6C4B – Disorders due to use of volatile inhalants
  • 6C4C – Disorders due to use of methylene-dioxymethamphetamine [MDMA] or related drugs, including methylene-dioxyamphetamine [MDA]
  • 6C4E – Disorders due to use of other specified psychoactive substances, including medications
  • 6C4F – Disorders due to use of multiple specified psychoactive substances, including medications
  • 6C4G – Disorders due to use of unknown or unspecified psychoactive substances
  • 6C4H – Disorders due to use of non-psychoactive substances
  • 6C4Y – Other specified disorders due to substance use
  • 6C4Z – Disorders due to substance use, unspecified

Foundation entity

Disorders due to use of dissociative drugs including ketamine or phencyclidine (PCP) – http://id.who.int/icd/entity/470484338

Allowed postcoordination axes

Part of: 06: Mental, behavioural or neurodevelopmental disorders